Amicus Therapeutics' wound treatment fails late-stage trial

(Reuters) – U.S. drug developer Amicus Therapeutics Inc said on Wednesday its drug to treat wounds failed to meet the main goals of a late-stage clinical trial.

The company said its drug, when compared with a placebo, did not show a statistical significance in reducing the time taken for wounds to close in patients with epidermolysis bullosa, a skin disease that causes blisters.

Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar

Our Standards:The Thomson Reuters Trust Principles.

Leave a Reply

Your email address will not be published. Required fields are marked *